Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry W Moore

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|December 19, 2015
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerRui Xiong, Hitisha K Patel, Lauren M Gutgesell, et al.
Journal of Medicinal Chemistry|August 21, 2023
Structure-Activity Relationships of the Antimicrobial Peptide Natural Product ApidaecinKornelia J Skowron, Chetana Baliga, Tatum Johnson, et al.
Journal of Drug Delivery|January 10, 2015
Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastasesShijun Zhu, Walter Kisiel, Yang J Lu, et al.
RSC Chemical Biology|April 22, 2026
Keap1-Kelch-targeting protein-protein interaction inhibitors, but not reversibly-binding electrophiles, increase the thermostability of Keap1 in the cellular environmentSharadha Dayalan Naidu, Dina Dikovskaya, Jasmine M Walker, et al.
Journal of Medicinal Chemistry|August 21, 2018
Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) InhibitorsBenjamin G Richardson, Atul D Jain, Haranatha R Potteti, et al.
Journal of Medicinal Chemistry|October 19, 2022
Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2-<i>a</i>]pyrimidines as Inhibitors of Group 2 Influenza A VirusesSaad Alqarni, Laura Cooper, Jazmin Galvan Achi, et al.
European Journal of Medicinal Chemistry|May 3, 2025
Refinement of imidazo[2,1-a]pyrimidines in pursuit of potential drug candidates against group 2 influenza A virusesMalaika D Argade, Varada Anirudhan, Sean P Bradley, et al.
Journal of Drug Targeting|December 17, 2014
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibodyShijun Zhu, Walter Kisiel, Yang J Lu, et al.
Journal of Agricultural and Food Chemistry|September 18, 2020
SAR Study on Estrogen Receptor α/β Activity of (Iso)flavonoids: Importance of Prenylation, C-Ring (Un)Saturation, and Hydroxyl SubstituentsObinna C Mbachu, Caitlin Howell, Charlotte Simmler, et al.
Current Cancer Drug Targets|March 18, 2014
Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenograftsShijun Zhu, Terry W Moore, Nao Morii, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|December 19, 2015
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast CancerRui Xiong, Hitisha K Patel, Lauren M Gutgesell, et al.
Journal of Medicinal Chemistry|August 21, 2023
Structure-Activity Relationships of the Antimicrobial Peptide Natural Product ApidaecinKornelia J Skowron, Chetana Baliga, Tatum Johnson, et al.
Journal of Drug Delivery|January 10, 2015
Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastasesShijun Zhu, Walter Kisiel, Yang J Lu, et al.
RSC Chemical Biology|April 22, 2026
Keap1-Kelch-targeting protein-protein interaction inhibitors, but not reversibly-binding electrophiles, increase the thermostability of Keap1 in the cellular environmentSharadha Dayalan Naidu, Dina Dikovskaya, Jasmine M Walker, et al.
Journal of Medicinal Chemistry|August 21, 2018
Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) InhibitorsBenjamin G Richardson, Atul D Jain, Haranatha R Potteti, et al.
Journal of Medicinal Chemistry|October 19, 2022
Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2-<i>a</i>]pyrimidines as Inhibitors of Group 2 Influenza A VirusesSaad Alqarni, Laura Cooper, Jazmin Galvan Achi, et al.
European Journal of Medicinal Chemistry|May 3, 2025
Refinement of imidazo[2,1-a]pyrimidines in pursuit of potential drug candidates against group 2 influenza A virusesMalaika D Argade, Varada Anirudhan, Sean P Bradley, et al.
Journal of Drug Targeting|December 17, 2014
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibodyShijun Zhu, Walter Kisiel, Yang J Lu, et al.
Journal of Agricultural and Food Chemistry|September 18, 2020
SAR Study on Estrogen Receptor α/β Activity of (Iso)flavonoids: Importance of Prenylation, C-Ring (Un)Saturation, and Hydroxyl SubstituentsObinna C Mbachu, Caitlin Howell, Charlotte Simmler, et al.
Current Cancer Drug Targets|March 18, 2014
Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenograftsShijun Zhu, Terry W Moore, Nao Morii, et al.
Pageof 7